The Department of Health is consulting on “Amendments to the statutory scheme to control the prices of branded health service medicines”. The consultation concerns options for a further limit to the maximum price of prescription only, branded health service medicines and strengthening the information requirements for enforcement to enable fair and consistent application of the limit on price. The consultation closes on the 7th November.
Lots of stuff in there to discuss. Here’s one… the consultation document states that “the 2014 PPRS encourages innovation and the development of high value treatments by promoting a strong and profitable pharmaceutical industry that is both capable of and willing to invest in sustained research and development to encourage the future availability of new and improved medicines for the benefit of patients and the industry in this and other countries.” So, why should innovation be factored into the ICER? It’s double counting!
